Source comparison
Melanotan-1 Pharmacokinetics: Plasma Elimination vs Biological Effect Duration
The melanotan-1 half life reported in peer-reviewed pharmacology literature ranges from 30 to 40 minutes when administered intravenously, with most studies converging on approximately 33 minutes as the mean plasma elimination half life. This figure comes from
This comparison does not assign a generated winner or score.
- The melanotan-1 half life reported in peer-reviewed pharmacology literature ranges from 30 to 40 minutes when administered intravenously, with most studies converging on approximately 33 minutes as the mean plasma elimination half life. This figure comes from phase I and phase II clinical trials conducted in the 1990s and early 2000s, during which researchers measured plasma concentration of intact peptide using radioimmunoassay and HPLC-MS at timed intervals post-injection. The short melanotan-1 half life reflects rapid renal clearance. The 13-amino-acid peptide (afamelanotide, [Nle4-D-Phe7]-α-MSH) has a molecular weight of 1,646 Da, well below the 30,000–50,000 Da threshold where glomerular filtration becomes significantly restricted.
- Subcutaneous administration. The route used in virtually all research and clinical contexts. Extends the apparent half life due to depot formation and slower systemic absorption. Studies using subcutaneous afamelanotide implants (the FDA-approved formulation for erythropoietic protoporphyria) demonstrated controlled-release kinetics with detectable plasma levels for 60 days, though these implants release peptide continuously at nanogram levels rather than delivering a bolus dose. For standard subcutaneous injection of reconstituted melanotan 1 powder, absorption occurs over 2–4 hours with peak plasma concentration (Cmax) reached at approximately 3–6 hours post-injection, followed by the same rapid elimination phase once absorbed. The practical implication: subcutaneous dosing doesn't meaningfully extend the melanotan-1 half life once the peptide enters circulation, but it does create a delayed and prolonged absorption window that moderates the pharmacokinetic spike.
- The disconnect between a 33-minute melanotan-1 half life and weeks-long pigmentation lies in the mechanism of action. Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocytes with high affinity (Kd approximately 0.37 nM), triggering G-protein-coupled receptor activation that elevates intracellular cAMP levels within minutes. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). This transcription factor upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis. MITF increases expression of tyrosinase, TRP-1, and TRP-2. The enzymes responsible for converting tyrosine into eumelanin. This entire cascade, from receptor binding to increased melanin synthesis, takes 24–72 hours to reach peak activity and persists for days after the initiating peptide has been cleared from plasma. The synthesized melanin itself remains stable within melanosomes and is transferred to surround
- Our work with researchers using high-purity melanotan 1 consistently shows visible pigmentation increase beginning 48–72 hours after the first dose. Not during the 33-minute window when plasma concentration peaks. The short melanotan-1 half life governs clearance kinetics, but receptor occupancy time and downstream signal amplification determine biological outcome. This is why daily or every-other-day dosing protocols during the loading phase produce cumulative melanogenesis: each dose re-activates MC1R before the downstream signaling from the previous dose has fully resolved, creating overlapping waves of MITF expression and tyrosinase activity.